DOCKET NO: ISIS0064-100 (RTS-0175) **PATENT**

In the Claims:

Please amend claim 1 and add new claims 21-30 as follows.

1. (previously presented) An oligomeric compound comprising up to 50 ~~8 to 50~~ nucleobases in length and comprising SEQ ID NO:38 ~~targeted to a nucleic acid molecule encoding human dual specific phosphatase 5 (SEQ ID NO:10), wherein said compound inhibits the expression of human dual specific phosphatase 5 by at least 40%~~.

2. (Original) The compound of claim 1 which is an antisense oligonucleotide.

3. (Canceled).

~~4.~~ 3. (Original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

~~5.~~ 4. (Original) The compound of claim ~~4~~ 3 wherein the modified internucleoside linkage is a phosphorothioate linkage.

~~6.~~ 5. (Original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

~~7.~~ 6. (Original) The compound of claim ~~6~~ 5 wherein the modified sugar moiety is a 2'-O-methoxycthyl sugar moiety.

~~8.~~ 7. (Original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

~~9.~~ 8. (Original) The compound of claim ~~8~~ 7 wherein the modified nucleobase is a 5-methylcytosine.

9 ~~10.~~ (Original) The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

11. (Canceled).

10 ~~12.~~ (Original) A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

11 ~~13.~~ (Original) The composition of claim ~~12~~ 10 further comprising a colloidal dispersion system.

12 ~~14.~~ (Original) The composition of claim ~~12~~ 10 wherein the compound is an antisense oligonucleotide.

13 ~~15.~~ (Previously presented) A method of inhibiting the expression of dual specific phosphatase 5 in cells or tissues comprising contacting said cells or tissues *in vitro* with the compound of claim 1 so that expression of dual specific phosphatase 5 is inhibited.

16-20. (Canceled).

14 ~~21.~~ (new) A compound consisting of SEQ ID NO:38.

15 ~~22.~~ (new) The compound of claim ~~21~~ 14 which is an antisense oligonucleotide.

16 ~~23.~~ (new) The compound of claim ~~22~~ 15 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

17 ~~24.~~ (new) The compound of claim ~~23~~ 16 wherein the modified internucleoside linkage is a phosphorothioate linkage.

~~25.~~ (new) The compound of claim ~~22~~ wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

~~26.~~ (new) The compound of claim ~~25~~ wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

~~27.~~ (new) The compound of claim ~~22~~ wherein the antisense oligonucleotide comprises at least one modified nucleobase.

~~28.~~ (new) The compound of claim ~~27~~ wherein the modified nucleobase is a 5-methylcytosine.

~~29.~~ (new) The compound of claim ~~22~~ wherein the antisense oligonucleotide is a chimeric oligonucleotide.

~~30.~~ (new) The compound of claim 1 wherein the compound comprises up to 30 nucleobases.